– Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD achieving all primary and secondary endpoints; initiation of the first Phase 3 clinical trial expected in 2H 2024 – – Dosed first patient in Phase 2 VERONA clinical trial of EYP-1901 in DME; topline data expected in 1Q 2025 – – Phase 2 PAVIA clinical trial topline data of EYP-1901 in moderately severe-to-severe NPDR anticipated in 2Q 2024 – – Announced appointment of Ramiro Ribeiro, M.D., Ph.D. as Chi ...

The market expects EyePoint Pharmaceuticals (EYPT) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.Our " ...

WATERTOWN, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) --  EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 7, 2024 to report its fourth quarter and full-year 2023 financial results and highlight recent corporate developments. To access the live conference call, please register using the au ...

zoranmEyePoint (NASDAQ:EYPT) has a potential blockbuster with EYP-1901 after a successful P2 trial that met all its endpoints in a very promising development. It sold off its remaining drug YUTIQ and reverted to a pure development company, betting the bank on EYP-1901. EYP-1901 has three possible uses (Wet AMD, NPDR and DME) each of which are multi-billion dollar markets, but after rising 400%+ in less than a year, the stock isn't a home run anymore and risks remain. FinVizA quick recap, the company de ...

WATERTOWN, Mass., Feb. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 49,000 s ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock char ...

股价表现 - EyePoint Pharmaceuticals (EYPT)上周收盘价为$29.71，过去四周上涨了30.5%[1] - 华尔街分析师设定的短期价格目标显示，股票仍有很大上涨空间，平均价格目标为$39，上涨潜力为31.3%[1] 盈利前景 - 分析师们对公司的盈利前景持乐观态度，预计公司将报告比他们之前估计的更好的收益[4] - 分析师们在调高EPS估计方面达成了强烈一致，这可能是预期股票上涨的合理理由[9]

Subgroup analyses underscore favorable clinical profile and durability of EYP-1901Presentations highlight previously reported positive Phase 2 DAVIO 2 topline results showing all primary and secondary endpoints were metResults presented today at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting WATERTOWN, Mass., Feb. 03, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients w ...

临床试验 - 公司正在进行EYP-1901的临床试验，针对湿性年龄相关性黄斑变性（wet AMD）、非增殖性糖尿病视网膜病变（NPDR）和糖尿病性黄斑水肿（DME）[46] 资金支持 - 公司预计现金、现金等价物和市场证券资产136亿美元将支持运营计划至2025年[46] YUTIQ权利 - 公司已将YUTIQ的全球权利授予Alimera，收到7500万美元的前期现金支付，并将在2025年开始获得Alimera相关美国净销售的低至中等两位数的版税[55] 2023年第三季度财务表现 - 产品销售净额同比下降了92%，降至816,000美元[65] - 许可和合作协议收入同比增长了27087%，达到14,137,000美元[65] - 总营收同比增长了52%，达到15,202,000美元[65] - 研发支出同比增长了56%，达到17,363,000美元[65] - 销售和营销支出同比下降了92%，降至479,000美元[65] - 净亏损同比减少了32%，降至12,612,000美元[65] 2023年前九个月财务表现 - 产品销售净额同比下降了55%，降至13,483,000美元[75] - 许可和合作协议收入同比增长了11005%，达到17,768,000美元[75] - 总营收同比增长了4%，达到31,990,000美元[75] - 研发支出同比增长了37%，达到46,711,000美元[75] 资金情况 - 2023年9月30日，公司现金、现金等价物和可交易证券总额为1.36亿美元[88] - 2023年9月30日，公司通过ATM以每股11.05美元的加权平均价格出售902,769股普通股，净收益约为960万美元[87] - 2023年9月30日，公司通过销售可交易证券获得净现金4640万美元[91] - 2023年9月30日，公司用于购买资产和设备的现金为260万美元[91] - 2023年9月30日，公司用于偿还SVB贷款的现金为4,050万美元[91] - 2023年9月30日，公司用于熄灭与SVB贷款相关的债务成本的现金为140万美元[91] - 2023年9月30日，公司通过ATM出售902,769股普通股，净收益960万美元[91] - 2022年9月30日，公司用于购买可交易证券的现金为4860万美元[91] - 2022年9月30日，公司用于购买资产和设备的现金为160万美元[91] - 2022年9月30日，公司用于偿还CRG贷款的现金为3820万美元[92]